Office of Pediatric Therapeutics, US Food and Drug Administration, Silver Spring, Maryland, USA.
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy & Epidemiology, Department of Pharmaceutical Sciences, University Basel, Basel, Switzerland.
Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5695. doi: 10.1002/pds.5695. Epub 2023 Sep 10.
Given limited information available on real-world data (RWD) sources with pediatric populations, this study describes features of globally available RWD sources for pediatric pharmacoepidemiologic research.
An online questionnaire about pediatric RWD sources and their attributes and capabilities was completed by members and affiliates of the International Society for Pharmacoepidemiology and representatives of nominated databases. All responses were verified by database representatives and summarized.
Of 93 RWD sources identified, 55 unique pediatric RWD sources were verified, including data from Europe (47%), United States (38%), multiregion (7%), Asia-Pacific (5%), and South America (2%). Most databases had nationwide coverage (82%), contained electronic health/medical records (47%) and/or administrative claims data (42%) and were linkable to other databases (65%). Most (71%) had limited outside access (e.g., by approval or through local collaborators); only 10 (18%) databases were publicly available. Six databases (11%) reported having >20 million pediatric observations. Most (91%) included children of all ages (birth until 18th birthday) and contained outpatient medication data (93%), while half (49%) contained inpatient medication data. Many databases captured vaccine information for children (71%), and one-third had regularly updated data on pediatric height (31%) and weight (33%). Other pediatric data attributes captured include diagnoses and comorbidities (89%), lab results (58%), vital signs (55%), devices (55%), imaging results (42%), narrative patient histories (35%), and genetic/biomarker data (22%).
This study provides an overview with key details about diverse databases that allow researchers to identify fit-for-purpose RWD sources suitable for pediatric pharmacoepidemiologic research.
鉴于全球范围内可用于儿科人群的真实世界数据(RWD)来源的信息有限,本研究描述了全球可用的儿科药物流行病学研究 RWD 来源的特点。
国际药物流行病学学会的成员和附属机构以及指定数据库的代表在线填写了一份关于儿科 RWD 来源及其属性和功能的问卷。所有回复均由数据库代表验证并进行总结。
在确定的 93 个 RWD 来源中,有 55 个经核实的独特儿科 RWD 来源,包括来自欧洲(47%)、美国(38%)、多区域(7%)、亚太地区(5%)和南美洲(2%)的数据。大多数数据库具有全国范围的覆盖(82%),包含电子健康/医疗记录(47%)和/或行政索赔数据(42%),并且可以与其他数据库链接(65%)。大多数数据库(71%)的外部访问权限有限(例如,需要获得批准或通过当地合作者);只有 10 个(18%)数据库可以公开获取。有 6 个数据库(11%)报告了超过 2000 万例儿科观察。大多数数据库(91%)包含所有年龄段的儿童(出生至 18 岁生日),包含门诊用药数据(93%),而一半数据库(49%)包含住院用药数据。许多数据库都记录了儿童疫苗信息(71%),三分之一的数据库定期更新儿科身高(31%)和体重(33%)数据。其他儿科数据属性包括诊断和合并症(89%)、实验室结果(58%)、生命体征(55%)、设备(55%)、成像结果(42%)、患者病史叙述(35%)和遗传/生物标志物数据(22%)。
本研究提供了一个概述,详细介绍了各种允许研究人员识别适合儿科药物流行病学研究的 RWD 来源的数据库。